Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-09-17
2004-02-10
Eyler, Yvonne (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S138100, C424S139100, C424S145100, C424S155100, C424S158100, C530S350000, C530S388100, C530S389100
Reexamination Certificate
active
06689744
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the activation of Notch receptor signaling to decrease cancer cell proliferation.
BACKGROUND OF THE INVENTION
Notch encodes a large protein with a single transmembrane domain, a large extracellular domain that has many tandem EGF-like repeats. Notch receptor is a signaling molecule that functions in cell development and differentiation. The Notch family includes several members for the receptor as well as ligand. Binding of ligand to a Notch receptor triggers the cleavage of the receptor at a site in the intracellular domain (ICD), releasing the activated form of the receptor which then migrates to the nucleus.
For men, prostate cancer is the second most fatal cancer after lung cancer. In advanced stages, prostate cancer metastasizes to the bone. Depending on the stage of the cancer, prostate cancer treatment involves one or a combination of the following therapies: surgery to remove the cancerous tissue, radiation therapy, chemotherapy, androgen deprivation (e.g., hormonal therapy) in the case of prostate cancer. The majority of patients who undergo hormone therapy progress to develop androgen-independent disease. Currently, there is no effective treatment for the 20-40% of prostate cancer patients who develop recurrent disease after surgery or radiation therapy, or for those in whom the cancer has metastasized at the time of diagnosis. Chemotherapy has its toxic side effects, especially in elderly patients. There is a need for new forms of prostate cancer therapy.
The present invention provides alternative methods of treating cancer that overcome the limitations of conventional therapeutic methods as well as offer additional advantages that will be apparent from the detailed description below.
SUMMARY OF THE INVENTION
In one embodiment, the invention concerns a method of decreasing the proliferation of prostate cancer cells by activating the Notch receptor.
In other embodiments, the invention provides for methods of detecting, diagnosing and alleviating prostate cancer by contacting biological samples suspected of prostate cancer. Detection and diagnosis of prostate cancer in the biological sample may include determining level of Notch expression, effects of Notch ligands on Notch receptor, or probing the biological sample with Notch receptor. Treatment may include contacting the biological sample with agonists to Notch 1 receptor or administration of a soluble Notch ligand.
In another embodiment, the invention provides an antibody which binds, preferably specifically, to Notch1. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.
Another embodiment of the invention concerns agonists and antagonists of Notch receptor as defined herein. In a particular embodiment, the agonist is an anti-Notch1 antibody, a soluble Notch1 ligand, or a small molecule.
In a still further embodiment, the invention concerns a method of identifying agonists to Notch receptor which comprise contacting the Notch receptor with a candidate molecule and monitoring a biological activity mediated by said Notch receptor. Preferably the Notch receptor is a native Notch receptor.
Another embodiment of the present invention is directed to the use of constitutively active Notch receptor, or an agonist thereof, for the preparation of a medicament useful in the treatment of a condition which is responsive to the constitutively active Notch receptor or an agonist thereof.
REFERENCES:
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: WO 91/05264 (1991-04-01), None
patent: WO 98/20142 (1998-05-01), None
patent: WO 99/04746 (1999-02-01), None
Curti, Crit. Rev. in Oncology/Hematology, 1993, vol. 14, pp. 29-39.*
Morris et al. Cancer, 2000, vol. 89(6), pp. 1329-1348.*
Gura, Science, 1997, vol. 278, pp. 1041-1042.*
Weinstein et al. Curr. Pharm. Des., 2000, 6(4), pp. 473-483.*
Artavanis-Tsakonas et al., “Notch Signaling.”Science, 268:225-232 (Apr. 14, 1995).
Gingrich et al., “Androgen-Independent Prostate Cancer Progression in the TRAMP Model.”Cancer Research57:4687-4691 (Nov. 1, 1997).
Gingrich et al., “Metastatic Prostate Cancer in a Transgenic Mouse.”Cancer Research. 56:4096-4102 (Sep. 15, 1996).
Gingrich et al., “Pathologic Progression of Autochthonous Prostate Cancer in the TRAMP Model.”Prostate Cancer and Prostatic Diseases. 2:70-75 (1995).
Greenberg et al., “Prostate Cancer in a Transgenic Mouse.”Proc. Natl. Acad. Sci. USA92:3439-3443 (1995).
Hayward et al., “Epithelial Development in the Rat Ventral Prostate, Anterior Prostate and Seminal Vesicle.”Acta Anatomica155:81-93 (1996).
Honjo, Tasuku., “The Shortest Path From the Surface to the Nucleus: RBP-J&kgr;/Su (H) Transcription Factor.”Genes to Cells. 1:1-9 (1996).
Lewis et al., “Distinct Expression Patterns of Notch Family Receptors and Ligands During Development of the Mammalian Inner Ear.”Mechanisms of Develop. 78:159-163 (1998).
Nofziger et al., “Notch Signaling Imposes Two Distinct Blocks in the Differentiation of C2C12 Myoblasts.”Development. 126 (1689-1702) (1999).
Nye et al., “An Activated Notch Suppresses Neurogenesis and Myogenesis But Not Gliogenesis in Mammalian Cells,”Development120:2421-2430 (1994).
Sias et al., “ELISA for Quantitcation of the Extracellular Domain of p185HER2 in Biological Fluids.”Journal of Immunological Methods132 (1):73-80 (1990).
Zheng et al., “Heregulin Enhances Regenerative Proliferation in Postnatal Rat Utricular Sensory Epithelium After Ototoxic Damage. ”J. Neurocytology28:901-912 (1999).
Lindsell et al., “Jagged: A Mammalian Ligand That Activates Notchl.”Cell. 80:909-917 (Mar. 1995).
Luo et al., “Isolation and Functional Analysis of a cDNA for Human Jagged2, a Gene Encoding a Ligand for the Notchl Receptor.”Mol. Cell. Bio. 17(10):6057-6067 (Oct. 1997).
Shou et al., “Dynamics of Notch Expression During Murine Prostate Development and Tumorigenesis.”Cancer Research .61:7291-7297 (Oct. 2001).
Zlobin et al., “Toward The Rational Design of Cell Fate Modifiers: Notch Signaling as a Target for Novel Biopharmaceuticals.”Current Pharm. Biotech. 1:83-106 (2000).
Gao Wei-Qiang
Koeppen Hartmut
Ross Sarajane
Shou Jianyong
Andres Janet L.
Carpenter David A.
Eyler Yvonne
Genentech Inc.
LandOfFree
Notch receptor agonists and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Notch receptor agonists and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Notch receptor agonists and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3325011